ARCT Q3 2022 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena

ARCTArcturus Therapeutics Holdings Inc.

$210M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+448.6% YoY

Gross Profit

-$24M-181.9% margin

Operating Income

-$37M-275.3% margin

Net Income

-$35M-263.8% margin

EPS (Diluted)

$-1.30

QoQ Revenue Growth

-50.7%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$45M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$294M

Total Liabilities

$148M

Stockholders' Equity

$146M

Cash & Equivalents

$238M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$2M	+448.6%
Gross Profit	-$24M	-$43M	+43.4%
Operating Income	-$37M	-$54M	+31.6%
Net Income	-$35M	-$54M	+34.8%